UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | V | W | Z
Number of items: 160.

A

Ajzensztejn, D; Hegde, V; Lee, SM; (2006) Tumour lysis syndrome following treatment with standard second-line docetaxel for non-small cell lung cancer. Journal of Clinical Oncology , 24 (15) 2389 - 2391.

Alonzi, R; Hoskin, P; (2006) Functional imaging in clinical oncology: Magnetic resonance imaging- and computerised tomography-based techniques. CLINICAL ONCOLOGY , 18 (7) 555 - 570.

Arkenau, H-T; (2006) 42nd annual meeting of the American society of clinical oncology, Atlanta, USA, 2006: Adjuvant treatment for colon and rectal cancer. Advances in Gastrointestinal Cancers , 4 (2) 21 - 22.

Arkenau, T; Cunningham, D; Mita, MM; Ochoa, L; Rowinsky, EK; Kuhn, J; ... Tolcher, AW; + view all (2006) A Phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Advances in Gastrointestinal Cancers , 4 (1) 20 - 21.

Arnould, S; Spanswick, VJ; Macpherson, JS; Hartley, JA; Thurston, DE; Jodrell, DI; Guichard, SM; (2006) Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. Mol Cancer Ther , 5 (6) 1602 - 1609. 10.1158/1535-7163.MCT-06-0018.

Arnould, S; Spanswick, VJ; Macpherson, JS; Hartley, JA; Thurston, DE; Jodrell, DI; Guichard, SM; (2006) Time-dependent cytotoxicity induced by SJU-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. MOL CANCER THER , 5 (6) 1602 - 1609. 10.1158/1535-7163.MCT-06-0018.

Ayaru, L; Pereira, SP; Meyer, T; Davidson, BR; Burroughs, AK; Williams, R; Behboudi, S; (2006) Alpha-fetoprotein specific CD4(+) T cell responses are unmasked during transarterial embolisation in hepatocellular carcinoma. In: GUT. (pp. A24 - A24). B M J PUBLISHING GROUP

Ayaru, L; Pereira, SP; Meyer, T; Davidson, BR; Burroughs, AK; Williams, R; Behboudi, S; (2006) Alpha-fetoprotein specific CD4+ T cell responses are unmasked during transarterial embolisation in hepatocellular carcinoma. In: JOURNAL OF HEPATOLOGY. (pp. S11 - S11). ELSEVIER SCIENCE BV

B

Begent, R; (2006) Developing Integrated Informatics Platform for Cancer Research. In: Nagl, S, (ed.) Cancer Bioinformatics: From Therapy Design to Treatment. (45 - 55). John Wiley & Sons: Chichester.

Beresford, M; Sanghera, B; Wong, WL; Makris, A; (2006) Imaging of primary breast cancer with F-18-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour. SPRINGER, 233 SPRING STREET, NEW YORK, NY 10013 USA

Beresford, MJ; Burcombe, R; Ah-See, ML; Stott, D; Makris, A; (2006) Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer. CLINICAL ONCOLOGY , 18 (6) 453 - 458.

Beresford, MJ; Chin, Y; Burcombe, Y; Ah-See, M; Makris, A; (2006) Clinical response assessment after 2 cycles of neoadjuvant chemotherapy for primary breast cancer fails to predict for final clinical response, but does predict for pathological complete response. In: Journal of Clinical Oncology. (pp. 44S - 44S).

Beresford, MJ; Harris, AL; Ah-See, M; Daley, F; Padhani, AR; Makris, A; (2006) The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. BRITISH JOURNAL OF CANCER , 95 (12) 1683 - 1688.

Beresford, MJ; Padhani, AP; Taylor, NJ; Ah-See, M-L; Stirling, JJ; Makris, A; ... Collins, DJ; + view all (2006) Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. Journal of Magnetic Resonance Imaging , 24 (6) 1316 - 1325. 10.1002/jmri.20768.

Beresford, MJ; Wilson, GD; Makris, A; (2006) Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Research , 8 (6)

Bielack, S; Sydes, M; Butterfass-Bahloul, T; Anninga, J; Benninger-Doring, G; Calaminus, G; ... Bernstein, M; + view all (2006) Successful multinational implementation of the European and American Osteosarcoma study EURAMOS-1 within the European Science Foundation's ECT-EUROCORES scheme. In: EMSOS, Moscow May 2006.

Bilancio, A; Okkenhaug, K; Camps, M; Emery, JL; Ruckle, T; Rommel, C; Vanhaesebroeck, B; (2006) Key role of the p110 delta isoforrn of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110 delta function in B cells. BLOOD , 107 (2) 642 - 650. 10.1182/blood.2005-07-3041.

Bilancio, A; Okkenhaug, K; Camps, M; Emery, JL; Ruckle, T; Rommel, C; Vanhaesebroeck, B; (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood , 107 (2) 642 - 650. 10.1182/blood-2005-07-3041.

Billottet, C; Grandage, VL; Gale, RE; Quattropani, A; Rommel, C; Vanhaesebroeck, B; Khwaja, A; (2006) A selective inhibitor of the p110 delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. ONCOGENE , 25 (50) 6648 - 6659. 10.1038/sj.onc.1209670.

Blay, J; Le, CA; Whelan, J; Van, OA; Ray-Coquard, I; Judson, I; ... Van, GM; + view all (2006) Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of the EORTC Soft Tissue and Bone Sarcoma Group. In: ASCO, Atlanta June 2006.

Blay, J; Le Cesne, A; Whelan, J; Van Oosterom, A; Ray-Coquard, I; Judson, L; ... Van Glabbeke, M; + view all (2006) Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 524S - 524S). AMER SOC CLINICAL ONCOLOGY

Boone, JJM; Hochhauser, D; Hartley, JA; (2006) Modulation of the repair of cisplatin-induced DNA interstrand crosslinks by trastuzumab. In: EJC SUPPL. (pp. 151 - 151). PERGAMON-ELSEVIER SCIENCE LTD

Bourhis, J; Overgaard, J; Audry, H; Ang, KK; Saunders, M; Bernier, J; ... Pignon, JP; + view all (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. , 368 (9538) 843 - 854. 10.1016/S0140-6736(06)69121-6.

Brooks, S; Daley, F; Johns, P; Brandner, S; Short, SC; (2006) Pescadillo and CYP1B1: Novel metabolic targets in glioma. In: RADIOTHERAPY AND ONCOLOGY. (pp. S72 - S73). ELSEVIER IRELAND LTD

Buchmueller, K; Bailey, S; Matthews, D; Register, J; Bruce, CD; O'Hare, C; ... Lee, M; + view all (2006) Molecular recognition of polyamides with DNA: A study on the strong binding of f-ImPyIm to its cognate DNA, ACGCGT. In: ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. (pp. 678 - ?).

Buchmueller, KL; Bailey, SL; Matthews, DA; Taherbhai, ZT; Register, JK; Davis, ZS; ... Lee, M; + view all (2006) Physical and structural basis for the strong interactions of the -ImPy- central pairing motif in the polyamide f-ImPyIm. BIOCHEMISTRY-US , 45 (45) 13551 - 13565. 10.1021/bi061245c.

Buffa, FM; Bentzen, SM; Atasoy, BM; Daley, FM; Richman, PI; Dische, S; ... Saunders, MI; + view all (2006) The response of head and neck tumours to radiotherapy may be influenced by the interaction between cell proliferation and vascularization. In: RADIOTHERAPY AND ONCOLOGY. (pp. S65 - S66).

Burcombe, R; Wilson, GW; Dowsett, M; Khan, I; Richman, PI; Daley, F; ... Makris, A; + view all (2006) Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Research , 8 (3) R31 - ?. 10.1186/bcr1508.

Burton, C; Linch, D; Hoskin, P; Milligan, D; Dyer, MJS; Hancock, B; ... Cunningham, D; + view all (2006) A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. BRITISH JOURNAL OF CANCER , 94 (6) 806 - 813.

C

Carnell, DM; Smith, RE; Daley, FM; Saunders, MI; Bentzen, SM; Hoskin, PJ; (2006) An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. International Journal of Radiation Oncology Biology Physics , 65 (1) 91 - 99.

Caroline, R; (2006) I was saved from death by cells harvested from my bones. The Daily Mail

Carrasco, DR; Fenton, T; Sukhdeo, K; Protopopova, M; Enos, M; You, MJ; ... DePinho, RA; + view all (2006) The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell , 9 (5) 379 - 390. 10.1016/j.ccr.2006.03.028.

Cave, J; Davis, B; Lee, SM; Jones, A; (2006) A randomised controlled trial comparing symptom-based and tumour-based teaching for undergraduates medical students. In: (Proceedings) 2006 NCRI Cancer Conference, Birmingham.. (pp. 192 - ?). Annals of Oncology

Cerone, MA; Londoño-Vallejo, JA; Autexier, C; (2006) Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance. Oncogene , 25 (56) 7411 - 7420. 10.1038/sj.onc.1209727.

Cerone, MA; Londoño-Vallejo, JA; Autexier, C; (2006) Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther , 5 (7) 1669 - 1675. 10.1158/1535-7163.MCT-06-0033.

Chang, JC; Makris, A; Hilsenbeck, SJ; Hackett, JR; Jeong, J; Liu, M; ... Shak, S; + view all (2006) Gene expression profiles in formalin-fixed, paraffin-embedded (FFPE) core biopsies predict docetaxel chemosensitivity. In: Journal of Clinical Oncology. (pp. 12S - 12S).

Channel, 5N; (2006) Cancer drug battle. UNSPECIFIED

Chin, Y; Ravichandran, D; Makris, A; (2006) Exemestane after non-steroidal aromatase inhibitors for post-menopaual women with advanced breast cancer. In: european Journal of Cancer. (pp. 167 - ?).

Chin, YS; Bullard, J; Bryant, L; Bownes, P; Ostler, P; Hoskin, PJ; (2006) High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. CLINICAL ONCOLOGY , 18 (7) 474 - 479.

Chong, G; Bhatnagar, A; Cunningham, D; Cosgriff, TM; Harper, PG; Steward, W; ... Carmichael, J; + view all (2006) Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol , 17 (3) 437 - 442. 10.1093/annonc/mdj090.

Chow, E; Hoskin, P; van der Linden, Y; Bottomley, A; Velikova, G; (2006) Quality of life and symptom end points in palliative bone metastases trials. ELSEVIER SCIENCE LONDON, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND

Chow, E; Hoskin, PJ; Wu, J; Roos, D; van der Linden, Y; Hartsell, W; ... Pater, J; + view all (2006) A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. ELSEVIER SCIENCE LONDON, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND

Cleator, S; Makris, A; Powles, T; (2006) Response to letter "Analysis of breast cancer survival by clinical response to neoadjuvant chemoendocrine therapy" by Bogaerts et al. (Ann Oncol 2006; 17 : 352-353). UNSPECIFIED

Cutillas, PR; Khwaja, A; Graupera, M; Pearce, W; Gharbi, S; Waterfield, M; Vanhaesebroeck, B; (2006) Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. P NATL ACAD SCI USA , 103 (24) 8959 - 8964. 10.1073/pnas.0602101103. Gold open access

D

Daniels, S; Statham, P; Globe, D; Seddon, B; Whelan, J; (2006) Piloting a novel method of administration – Moving inpatient treatments to ambulatory care. In: British Oncology Pharmacists Association, Bournemouth October 2006.

de Bruin, EC; van de Velde, CJ; van de Pas, S; Nagtegaal, ID; van Krieken, JH; Gosens, MJ; ... Marijnen, CA; + view all (2006) Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res , 12 (21) 6432 - 6436. 10.1158/1078-0432.CCR-06-0231.

Dische, S; Rojas, A; Saunders, M; (2006) What can be learnt from a final follow up study of the chart pilot study? In: Radiotherapy & Oncology. (pp. S131 - S131).

Donovan, E; Coles, C; Westbury, C; Yarnold, J; (2006) Breast. In: External Beam Therapy. Oxford University Press

E

El, EE; Dearling, J; Huhalov, A; Robson, P; Neri, D; van, DGA; ... Pedley, RB; + view all (2006) Targeting the tumour vasculature: therapeutic efficacy of a 131I-labeled antibody against the ED-B domain of fibronectin. In: (Proceedings) NCRI Cancer Conference proceedings. (pp. 63 - ?).

El, EE; Dearling, J; Huhalov, A; Robson, P; Neri, D; van, DGA; ... Pedley, RB; + view all (2006) Targeting tumour vasculature in human colorectal xenografts using an antibody against the extra-domain B of fibronectin. BACR/BMS Tumour vasculature: New targets and Therapies. In: Angiogenesis. (pp. 18 - ?).

F

Flores, L; Staples, A; Mackay, H; Howard, C; Uthe, P; Sexton, J; ... Lee, M; + view all (2006) Synthesis and evaluation of LVF-I-141: An intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase II alpha promoter. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY , 231 ? - ?.

Flores, LV; Staples, AM; Mackay, H; Howard, CM; Uthe, PB; Sexton, JS; ... Lee, M; + view all (2006) Synthesis and evaluation of an intercalator-polyamide hairpin designed to target the inverted CCAAT box 2 in the topoisomerase II alpha promoter. CHEMBIOCHEM , 7 (11) 1722 - 1729. 10.1002/cbic.200600155.

Ford, HER; Yap, YS; Miles, DW; Makris, A; Hall, M; Miller, L; ... Johnston, SRD; + view all (2006) A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology , 58 (6) 809 - 815.

Foukas, LC; Claret, M; Pearce, W; Okkenhaug, K; Meek, S; Peskett, E; ... Vanhaesebroeck, B; + view all (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature , 441 (7091) 366 - 370. 10.1038/nature04694.

Foukas, LC; Claret, M; Pearce, W; Okkenhaug, K; Meek, S; Peskett, E; ... Vanhaesebroeck, B; + view all (2006) Critical role for the p110 alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. NATURE , 441 (7091) 366 - 370. 10.1038/nature04694.

Fox, J; Alabassi, A; Patkar, V; Rose, T; Black, E; (2006) An ontological approach to modelling tasks and goals. COMPUT BIOL MED , 36 (7-8) 837 - 856. 10.1016/j.compbiomed.2005.04.011.

Fox, J; Patkar, V; Thomson, R; (2006) Decision support for health care: the PROforma evidence base. Inform Prim Care , 14 (1) 49 - 54.

Friedmann, BJ; Caplin, M; Savic, B; Shah, T; Lord, CJ; Ashworth, A; ... Hochhauser, D; + view all (2006) Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. MOL CANCER THER , 5 (2) 209 - 218. 10.1158/1535-7163.MCT-05-0239.

G

Glynne-Jones, R; Grainger, J; Harrison, M; Ostler, P; Makris, A; (2006) Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? BRITISH JOURNAL OF CANCER , 94 (3) 363 - 371.

Graham, J; Wagner, K; Plummer, R; Wiedenmann, B; Cassidy, J; Kowal, K; ... Calvert, H; + view all (2006) Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 97S - 97S). AMER SOC CLINICAL ONCOLOGY

Green, AJ; Begent, RHJ; (2006) Generation of voxel phantoms to investigate the effect of statistical noise on image analysis programs. EUR J NUCL MED MOL I , 33 S319 - S319.

Gupta, N; Saleem, A; Kotz, B; Osman, S; Aboagye, EO; Phillips, R; ... Price, PM; + view all (2006) Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. CLINICAL CANCER RESEARCH , 12 (10) 3115 - 3123.

H

Hamaguchi, A; Suggitt, M; Howard, PW; Gregson, SJ; Kasprzyk, PG; Thurston, DE; Hartley, JA; (2006) DNA cross-linking and in vivo antitumour activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057 (DRG-16). In: EJC SUPPL. (pp. 96 - 96). PERGAMON-ELSEVIER SCIENCE LTD

Harland, SJ; Daugaard, G; Horwich, A; Mead, GM; Fossa, SD; Sokal, M; ... National, CRITCCSG; + view all (2006) The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2. In: Journal of Clinical Oncology. (pp. 239S, 4590 - ?).

Ho, E; Vassileva, V; Lim-Soo, P; Allen, C; Piquette-Miller, M; (2006) Impact of localized, sustained delivery of paclitaxel on the in vitro and in vivo regulation of P-glycoprotein. In: CLINICAL PHARMACOLOGY & THERAPEUTICS. (pp. P11 - P11). MOSBY, INC

Howard, PW; Chen, Z; Gregson, SJ; Stephenson, M; Klee, S; Hartley, JM; ... Thurston, DE; + view all (2006) The design, synthesis and biological evaluation of a set of C2-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepine dimers. EJC SUPPL , 4 (12) 95 - 95.

Howard, PW; Tiberghien, A; Gregson, SJ; Kang, GD; Stephenson, M; Kiakos, K; ... Thurston, DE; + view all (2006) Design, synthesis and evaluation of extended heterocycle linked C81C8 ' pyrrolo[2,1-c][1,4]benzodiazepine DNA cross-linking agents. In: EJC SUPPL. (pp. 93 - 93). PERGAMON-ELSEVIER SCIENCE LTD

Hughes, R; Glynne-Jones, R; Grainger, J; Richman, P; Makris, A; Harrison, M; ... Novell, JR; + view all (2006) Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? International Journal of Colorectal Disease , 21 (1) 11 - 17.

J

Jagsi, R; Makris, A; Goldberg, S; Taghian, A; (2006) Intra-European differences in the radiotherapeutic management of breast cancer: A survey study. CLINICAL ONCOLOGY , 18 (5) 369 - 375.

Jones, SF; Plummer, ER; Burris, HA; Razak, AR; Meluch, AA; Bowen, CJ; ... Calvert, AH; + view all (2006) Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY , 24 (18) 85S - 85S.

Juergens, C; Weston, C; Lewis, I; Whelan, J; Paulussen, M; Oberlin, O; ... Craft, A; + view all (2006) Safety Assessment of Intensive Induction With Vincristine, Ifosfamide, Doxorubicin, and Etoposide (VIDE) in the Treatment of Ewing Tumors in the EURO-E.W.I.N.G. 99 Clinical Trial. Pediatric Blood and Cancer , 47 (1) 22 - 29.

Julia, LS; (2006) You Don't Have to Smoke to Get Lung Cancer. Sunday Telegraph, Stella Magazine

K

Kang, S; Denley, A; Vanhaesebroeck, B; Vogt, PK; (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A , 103 (5) 1289 - 1294. 10.1073/pnas.0510772103.

Kaufmann, M; Hortobagyi, GN; Goldhirsch, A; Scholl, S; Makris, A; Valagussa, P; ... von Minckwitz, G; + view all (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. JOURNAL OF CLINICAL ONCOLOGY , 24 (12) 1940 - 1949.

Khanduri, S; Gerrard, G; Barton, R; Mulvenna, P; Lee, SM; (2006) Clinical Trials assessing the optimal management of brain metastases-the state of play. Clinical Oncology , 18 (10) 744 - 746.

Khoja, L; Mulyati, M; Lee, SM; (2006) Secondline chemotherapy in NSCLC. Lung Cancer in Practice , 3 (1) 6 - 7.

Kluza, J; Mazinghien, R; Irwin, H; Hartley, JA; Bailly, C; (2006) Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide. ANTI-CANCER DRUG , 17 (2) 155 - 164.

Kogelberg, H; Sharma, SK; Qureshi, U; Tolner, B; Lowdell, M; Shabakhti, H; ... Chester, KA; + view all (2006) Clearance mechanism of a mannoseylated antibody enzyme fusion protein used in experimental cancer therapy. In: (Proceedings) NCRI Cancer Conference Proceedings. (pp. 65 - ?).

Kogelberg, H; Sharma, SK; Qureshi, U; Tolner, B; Lowdell, M; Shahbakhti, H; ... Chester, KA; + view all (2006) Clearance Mechanism Of A Mannosylated Antibody-Enzyme Fusion Protein Used In Experimental Cancer Therapy. In: (Proceedings) NCRI Cancer Conference Proceedings.

Koukourakis, MI; Bentzen, SM; Giatromanolaki, A; Wilson, GD; Daley, FM; Saunders, MI; ... Harris, AL; + view all (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. Journal of Clinical Oncology , 24 (5) 727 - 735. 10.1200/JCO.2005.02.7474.

L

Ladenstein, R; Whelan, J; Oberlin, O; Weston, C; Jurgens, H; (2006) Multivariate analysis based risk grouping of Ewing tumours with extrapulmonary metastatic disease. Results from the EURO EWING 99 Study. In: SIOP XXXVII meeting, Geneva Sept 2006. Ped Blood Cancer 2006;47(4):369.

Lai, CSL; Boshoff, C; Falzon, M; Lee, SM; (2006) Complete response to erlotinib therapy in brain metastases from recurrent NSCLC. Thorax , 61 (1) 91 - ?.

Lambros, MB; Simpson, PT; Jones, C; Natrajan, R; Westbury, C; Steele, D; ... Reis-Filho, JS; + view all (2006) Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest , 86 (4) 398 - 408. 10.1038/labinvest.3700390.

Last, K; Maharaj, L; Perry, J; Strauss, S; Fitzgibbon, J; Lister, TA; Joel, S; (2006) The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol , 17 , Article 5.

Le, NM; Sielaff, AM; Cooper, AJ; Mackay, H; Brown, T; Kotecha, M; ... Hartley, JA; + view all (2006) Binding of f-PIP, a pyrrole- and imidazole-containing triamide to the inverted CCAAT box-2 of the topoisomerase II alpha promoter and modulation of gene expression in cells. Bioorganic and Medicinal Chemistry Letters , 16 (24) 1661 - 1664.

Le, NM; Sielaff, AM; Cooper, AJ; Mackay, H; Brown, T; Kotecha, M; ... Hartley, JA; + view all (2006) Binding of f-PIP, a pyrrole- and imidazole-containing triamide to the inverted CCAAT box-2 of the topoisomerase II alpha promoter and modulation of gene expression in cells. BIOORG MED CHEM LETT , 16 (24) 6161 - 6164. 10.1016/j.bmcl.2006.09.043.

Lee, SM; (2006) Is EGFR expression important in non-small cell lung cancer? Thorax , 61 (2) 98 - 99.

Louise, J; (2006) Thalidomide makes a comeback-but at what cost? Morning Star

M

Maharaj, L; Popat, R; Chahwan, A; Lister, AT; Cavenagh, JD; Middleton, B; ... Joel, SP; + view all (2006) The novel HDAC inhibitor UCL67022 is highly potent in multiple myeloma and non-Hodgkin's lymphoma and is enhanced by bortezomib. In: BLOOD. (pp. 735A - 735A). AMER SOC HEMATOLOGY

Marelli, L; Stigliano, R; Triantos, C; Senzolo, M; Cholongitas, E; Davies, N; ... Burroughs, AK; + view all (2006) Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev , 32 (8) 594 - 606. 10.1016/j.ctrv.2006.08.002.

Masterson, LA; Spanswick, VJ; Hartley, JA; Begent, RH; Howard, PW; Thurston, DE; (2006) Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. BIOORG MED CHEM LETT , 16 (2) 252 - 256. 10.1016/j.bmcl.2005.10.017.

Masterson, LA; Spanswick, VJ; Hartley, JA; Begent, RH; Howard, PW; Thurston, DE; (2006) Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. Bioorganic and Medicinal Chemistry Letters , 16 (2) 252 - 256. 10.1016/j.bmcl.2005.10.017.

Mayer, A; Francis, RJ; Sharma, SK; Tolner, B; Springer, CJ; Martin, J; ... Begent, RH; + view all (2006) A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti-Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug. Clinical Cancer Research , 12 (21) 6509 - 6516.

Mayer, A; Francis, RJ; Sharma, SK; Tolner, B; Springer, CJ; Martin, J; ... Begent, RHJ; + view all (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. CLIN CANCER RES , 12 (21) 6509 - 6516. 10.1158/1078-0432.CCR-06-0769.

McGurk, CJ; Cummings, M; Koberle, B; Hartley, JA; Oliver, RT; Masters, JR; (2006) Regulation of DNA repair gene expression in human cancer cell lines. J CELL BIOCHEM , 97 (5) 1121 - 1136. 10.1002/jcb.20711.

McTiernan, A; Driver, D; Michelagnoli, MP; Kilby, AM; Whelan, JS; (2006) High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. ANN ONCOL , 17 (8) 1301 - 1305. 10.1093/annonc/mdl108.

McTiernan, A; Meyer, T; Michelagnoli, MP; Lewis, I; Whelan, JS; (2006) A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. PEDIATR BLOOD CANCER , 46 (3) 345 - 350. 10.1002/pbc.20562.

McTiernan, A; Whelan, J; Leahy, M; Woll, PJ; Judson, I; (2006) A phase II nonrandomised open-label study of liposomal daunorubicin (DaunoXome) in advanced soft tissue sarcoma. Sarcoma , 2006 10.1155/SARCOMA/41080. Gold open access

McTiernan, AM; Cassoni, AM; Driver, D; Michelagnoli, MP; Kilby, AM; Whelan, JS; (2006) Improving Outcomes After Relapse in Ewing’s Sarcoma: Analysis of 114 Patients From a Single Institution. Sarcoma , 2006 1 - 8. Gold open access

Mudie, NY; Swerdlow, AJ; Higgins, CD; Smith, P; Qiao, ZK; Hancock, BW; ... Linch, DC; + view all (2006) Risk of second malignancy after non-Hodgkin's lymphoma: A British cohort study. J CLIN ONCOL , 24 (10) 1568 - 1574. 10.1200/JCO.2005.04.2200.

Murugaesu, N; Schmid, P; Dancey, G; Agarwal, R; Holden, L; McNeish, I; ... Seckl, MJ; + view all (2006) Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol , 24 (30) 4862 - 4866. 10.1200/JCO.2006.06.2489.

N

Ng, QS; Goh, V; Fichte, H; Klotz, E; Fernie, P; Saunders, MI; ... Padhani, AR; + view all (2006) Lung cancer perfusion at multi-detector row CT: Reproducibility of whole tumor quantitative measurements. RADIOLOGY , 239 (2) 547 - 553.

O

O'Donnell, P; Diss, TC; Whelan, J; Flanagan, AM; (2006) Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. Skeletal Radiology , 35 (4) 345 - 350.

O'Donnell, P; Diss, TC; Whelan, J; Flanagan, AM; (2006) Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies. SKELETAL RADIOL , 35 (4) 233 - 239. 10.1007/s00256-005-0006-z.

Okkenhaug, K; Patton, DT; Bilancio, A; Garçon, F; Rowan, WC; Vanhaesebroeck, B; (2006) The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J Immunol , 177 (8) 5122 - 5128.

P

Pankhurst, T; Howie, AJ; Adu, D; Wallace, DMA; Lipkin, GW; (2006) Incidental neoplasms in renal biopsies. NEPHROLOGY DIALYSIS TRANSPLANTATION , 21 (1) 64 - 69. 10.1093/ndt/gfi149.

Patkar, V; Hurt, C; Steele, R; Love, S; Purushotham, A; Williams, M; ... Fox, J; + view all (2006) Evidence-based guidelines and decision support services: a discussion and evaluation in triple assessment of suspected breast cancer. BRIT J CANCER , 95 (11) 1490 - 1496. 10.1038/sj.bjc.6603470.

Patton, DT; Garden, OA; Pearce, WP; Clough, LE; Monk, CR; Leung, E; ... Okkenhaug, K; + view all (2006) Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol , 177 (10) 6598 - 6602.

Perisoglou, M; Seddon, B; Daniels, S; Mayne, N; Whelan, J; (2006) Incidence of delays in methotrexate toxicity in treatment of osteosarcoma. In: SIOP XXXVII meeting, Geneva Sept 2006. Ped Blood Cancer 2006;47(4):511.

Perumal, M; Pillai, RG; Barthel, H; Leyton, J; Latigo, JR; Forster, M; ... Aboagye, EO; + view all (2006) Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res , 66 (17) 8558 - 8564. 10.1158/0008-5472.CAN-06-0898.

Plummer, R; Lorigan, P; Evans, J; Steven, N; Middleton, M; Wilson, R; ... Calvert, H; + view all (2006) First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 456S - 456S). AMER SOC CLINICAL ONCOLOGY

Plummer, R; Vidal, L; Li, L; Shaw, H; Perrett, R; Shahidi, M; ... de Bono, J; + view all (2006) Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR. EJC SUPPL , 4 (12) 173 - 174.

Pors, K; Shnyder, SD; Teesdale-Spittle, PH; Hartley, JA; Zloh, M; Searcey, M; Patterson, LH; (2006) Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: Potential for development of tumor-selective N-oxides. J MED CHEM , 49 (24) 7013 - 7023. 10.1021/jm0608154.

Porschen, R; Kubicka, S; Grothey, A; Grateven, U; Kretzschmar, A; Greil, R; ... Schmiegel, W; + view all (2006) Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC). In: GASTROENTEROLOGY. (pp. A582 - A582). W B SAUNDERS CO-ELSEVIER INC

Purnell, B; Lingerfelt, B; Scott, A; Townes, H; Summerville, K; Hudson, S; ... Lee, M; + view all (2006) Novel (S)-(-)- and R-(+)-seco-iso-cyclopropylfurano[e]indoline-5,6,7-trimethoxyindole-2-carboxamide (iso-CFI) analogs of duocarmycin C2: synthesis and biological evaluation. Med Chem , 2 (2) 139 - 146.

Purnell, B; Sato, A; O'Kelley, A; Price, C; Summerville, K; Hudson, S; ... Hartley, JA; + view all (2006) DNA interstrand crosslinking agents: Synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD). BIOORG MED CHEM LETT , 16 (21) 5677 - 5681. 10.1016/j.bmcl.2006.08.005.

R

Rades, D; Stalpers, LJA; Schulte, R; Veninga, T; Basic, H; Engenhart-Cabilic, R; ... Hoskin, PJ; + view all (2006) Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. EUROPEAN JOURNAL OF CANCER , 42 (8) 1052 - 1056.

Rades, D; Stalpers, LJA; Veninga, T; Hoskin, PJ; (2006) Spinal reirradiation after short-course RT for metastatic spinal cord compression. International Journal of Radiation Oncology Biology Physics , 63 (3) 872 - 875.

Rades, D; Stalpers, LJA; Veninga, T; Rudat, V; Schulte, R; Hoskin, PJ; (2006) Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. The Journal of Urology , 175 (2) 552 - 556.

Rades, D; Walz, J; Stalpers, LJA; Veninga, T; Schulte, R; Obralic, N; ... Schild, SE; + view all (2006) Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: Results of a retrospective multi-center study. EUROPEAN UROLOGY , 49 (5) 846 - 852.

Ranson, M; Middleton, MR; Bridgewater, J; Lee, SM; Dawson, M; Jowle, D; ... Margison, GP; + view all (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res , 12 (5) 1577 - 1584. 10.1158/1078-0432.CCR-05-2198.

Ranson, R; Middleton, MR; Bridgewater, J; Lee, SM; Dawson, M; Jowle, D; ... Margison, GP; + view all (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA alkyltransferas: Phase 1 safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumours. Clinical Cancer Research , 12 (5) 1577 - 1584.

Ravn, P; Patel, A; Andre, M; Bicknell, R; Begent, R; Pedley, B; ... Meyer, T; + view all (2006) Generation of Antibodies to Magic Roundabout 4, Robo4 using Phage Display. In: (Proceedings) NCRI Cancer Conference Proceedings.

Rebholz, H; Panasyuk, G; Fenton, T; Nemazanyy, I; Valovka, T; Flajolet, M; ... Gout, IT; + view all (2006) Receptor association and tyrosine phosphorylation of S6 kinases. FEBS J , 273 (9) 2023 - 2036. 10.1111/j.1742-4658.2006.05219.x.

Reis-Filho, JS; Westbury, C; Pierga, JY; (2006) The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol , 59 (3) 225 - 231. 10.1136/jcp.2005.028324.

Rossi, C; Angelucci, A; Costantin, L; Braschi, C; Mazzantini, M; Babbini, F; ... Caleo, M; + view all (2006) Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. EUR J NEUROSCI , 24 (7) 1850 - 1856. 10.1111/j.1460-9568.2006.05059.x.

Ruszniewski, P; Delle Fave, G; Cadiot, G; Komminoth, P; Chung, D; Kos-Kudla, B; ... Rindi, G; + view all (2006) Well-differentiated gastric tumors/carcinomas. NEUROENDOCRINOLOGY , 84 (3) 158 - 164. 10.1159/000098007.

S

Sainz-Pastor, N; Tolner, B; Huhalov, A; Kogelberg, H; Lee, YC; Zhu, DL; ... Chester, KA; + view all (2006) Deglycosylation to obtain stable and homogeneous Pichia pastoris-expressed N-A1 domains of carcinoembryonic antigen. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES , 39 (1-3) 141 - 150. 10.1016/j.ijbiomac.2006.03.022.

Saunders, MI; Rojas, A; (2006) Burning issues in CERT. In: RADIOTHERAPY AND ONCOLOGY. (pp. S19 - S19).

Shah, T; Hochhauser, D; Frow, R; Quaglia, A; Dhillon, AP; Caplin, ME; (2006) Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J NEUROENDOCRINOL , 18 (5) 355 - 360. 10.1111/j.1365-2826.2006.01425.x.

Shanley, S; McReynolds, K; Ardern, JA; Ahern, R; Fernando, I; Yarnold, J; ... Easton, DAER; + view all (2006) Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clinical Cancer Research , 1 (12) 7025 - 7032.

Shanley, SBKS; S Evans G Tutt, AH; S Powles, TASA; R Easton D and Eeles, R; (2006) Acute Chemotherapy related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the UK. Clinical Cancer Research

Shaw, H; Plummer, R; Vidal, L; Perrett, R; Pilkington, M; Temple, G; ... De Bono, J; + view all (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. 127S - 127S). AMER SOC CLINICAL ONCOLOGY

Short, S; (2006) UNSPECIFIED In: (Proceedings) 3rd International Conference on Translational Research and Preclinical Strategies in Radiation Oncology.

Short, S; (2006) BBC 6 O'Clock news. UNSPECIFIED

Short, SC; Bourne, S; Martindale, C; Johnston, P; (2006) DNA repair after clinical radiation doses in gliomas and normal human astrocytes. In: NEURO-ONCOLOGY. (pp. 310 - 310).

Sizer, B; Makris, A; Barone, C; Mainwaring, P; Eggleton, P; (2006) QoL and resource use analysis of tegafur-uracil/LV or 5-FU/LV in first-line metastatic colorectal cancer (mCRC): Final results of a multicenter phase II study. In: Journal of Clinical Oncology. (pp. 178S - 178S).

Soffietti, R; Cornu, P; Delattre, JY; Grant, R; Graus, F; Grisold, W; ... Vecht, C; + view all (2006) EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. EUROPEAN JOURNAL OF NEUROLOGY , 13 (7) 674 - 681.

Spender, LC; Lucchesi, W; Bodelon, G; Bilancio, A; Karstegl, CE; Asano, T; ... Farrell, PJ; + view all (2006) Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol , 87 (Pt 10) 2859 - 2867. 10.1099/vir.0.82128-0.

Stephens, R; Hoskin, P; (2006) Clinical trials and modern advertising: The Lung Cancer Trials Flowchart. ELSEVIER SCIENCE LONDON, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND

Strauss, SJ; Maharaj, L; Hoare, S; Johnson, PW; Radford, JA; Vinnecombe, S; ... Lister, TA; + view all (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol , 24 (13) 2105 - 2112. 10.1200/JCO.2005.04.6789.

Strauss, SJ; Morschhauser, F; Rech, J; Repp, R; Solal-Celigny, P; Zinzani, PL; ... Lister, TA; + view all (2006) Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol , 24 , Article 24. 10.1200/JCO.2006.05.6291.

T

Thornton, AD; Ravn, P; Winslet, M; Chester, K; (2006) Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. BRIT J SURG , 93 (12) 1456 - 1463. 10.1002/bjs.5624.

Tolner, B; Hillyer, T; Smith, L; Begent, RHJ; Contreras, R; Chester, KA; (2006) A Recombinant Antibody-Enzyme Fusion Protein Produced in Pichia Pastoris in Compliance with EU Clinical Trials Directive for Phase I/II Cancer Trials. In: (Proceedings) NCRI Cancer Conference Proceedings.

Tolner, B; Smith, L; Begent, RHJ; Chester, KA; (2006) Expanded-bed adsorption immobilized-metal affinity chromatography. NAT PROTOC , 1 (3) 1213 - 1222. 10.1038/nprot.2006.127.

Tolner, B; Smith, L; Begent, RHJ; Chester, KA; (2006) Production of recombinant protein in Pichia pastoris by fermentation. NAT PROTOC , 1 (2) 1006 - 1021. 10.1038/nprot.2006.126.

V

Vanhaesebroeck, B; (2006) Charging the batteries to heal wounds through PI3K. Nat Chem Biol , 2 (9) 453 - 455. 10.1038/nchembio0906-453.

Venables, K; Miles, EA; Aird, EGA; Hoskin, PJ; (2006) What is the optimum breast plan: a study based on the START trial plans. British Journal of Radiology , 79 (945) 734 - 739.

Vukmanovic-Stejic, M; Zhang, Y; Cook, JE; Fletcher, JM; McQuaid, A; Masters, JE; ... Akbar, AN; + view all (2006) Human CD4(+)CD25(hi)Foxp3(+) regulatory T cells are derived by rapid turnover of memory populations in vivo. J CLIN INVEST , 116 (9) 2423 - 2433. 10.1172/JCI28941.

W

Wallace, DL; Berard, M; Soares, MVD; Oldham, J; Cook, JE; Akbar, AN; ... Beverley, PCL; + view all (2006) Prolonged exposure of naive CD8(+) T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. IMMUNOLOGY , 119 (2) 243 - 253. 10.1111/j.1365-2567.2006.02429.x.

Wells, G; Martin, CRH; Howard, PW; Sands, ZA; Laughton, CA; Tiberghien, A; ... Thurston, DE; + view all (2006) Design, synthesis, and biophysical and biological evaluation of a series of Pyrrolobenzodiazepine - Poly(N-methylpyrrole) conjugates. J MED CHEM , 49 (18) 5442 - 5461. 10.1021/jm051199z.

Whelan, J; Bielack, S; Marina, N; Smeland, S; Bernstein, M; (2006) . EURAMOS 1 - international randomised trial in a rare cancer: last of a soon-to-be extinct species or hope for the future? In: SIOP XXXVII meeting, Geneva Sept 2006. Ped Blood Cancer 2006;47(4):424.

Whelan, J; Dolbear, C; Davies, E; Moller, H; (2006) Where do teenagers and young adults receive treatment for cancer? In: UK Association of Cancer Registries and Netherlands Cancer Registry Conference, Amsterdam, October 2006.

Whelan, J; McTiernan, A; Weston, C; Douglas, C; Grimer, R; Cassoni, A; ... Lewis, I; + view all (2006) Consequences of different approaches to local treatment of Ewing's sarcoma within an international randomised controlled trial: Analysis of EICESS-92. In: Journal of Clinical Oncology. (pp. 528S - 528S).

Whelan, J; Seddon, B; Perisoglou, M; (2006) Management of osteosarcoma. Curr Treat Options Oncol , 7 (6) 444 - 455.

Whelan, JS; Cassoni, AM; Pollock, R; (2006) Bone. In: Price, P and Sikora, K, (eds.) Treatment of Cancer. : London.

Whelan, JS; McTiernan, A; Weston, C; Douglas, C; Grimer, R; Cassoni, A; ... Lewis, I; + view all (2006) Consequences of different approaches to local treatment of Ewing’s sarcoma within an international randomised controlled trial: analysis of EICESS-92. In: ASCO, Atlanta, June 2006.

Whelan, JS; Seddon, BM; Perisoglou, M; (2006) Current Management of Osteosarcoma. Current Treatment Options in Oncology , 7 444 - 455.

Wilson, GD; Saunders, MI; Dische, S; Daley, FM; Buffa, FM; Richman, PI; Bentzen, SM; (2006) Pre-treatment proliferation and the outcome of conventional and accelerated radiotherapy. EUROPEAN JOURNAL OF CANCER , 42 (3) 363 - 371.

Z

Zhao, Y; Thomas, HD; Batey, MA; Cowell, IG; Richardson, CJ; Griffin, RJ; ... Curtin, NJ; + view all (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. CANCER RES , 66 (10) 5354 - 5362. 10.1158/0008-5472.CAN-05-4275.

This list was generated on Sun Aug 31 03:21:52 2014 BST.